126 related articles for article (PubMed ID: 20836670)
1. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section.
Wen PY
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1367-9. PubMed ID: 20836670
[TBL] [Abstract][Full Text] [Related]
2. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Józwiak S; Stein K; Kotulska K
Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.
Lam C; Bouffet E; Tabori U; Mabbott D; Taylor M; Bartels U
Pediatr Blood Cancer; 2010 Mar; 54(3):476-9. PubMed ID: 19856393
[TBL] [Abstract][Full Text] [Related]
5. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
Komotar RJ; Starke RM; Connolly ES; Sisti MB
Neurosurgery; 2011 Apr; 68(4):N24-5. PubMed ID: 21792104
[No Abstract] [Full Text] [Related]
7. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Curran MP
Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
[TBL] [Abstract][Full Text] [Related]
8. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
[TBL] [Abstract][Full Text] [Related]
9. The mTOR inhibitor revolution rolls on.
Northrup H
Lancet Oncol; 2014 Dec; 15(13):1418-1419. PubMed ID: 25456358
[No Abstract] [Full Text] [Related]
10. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.
Perek-Polnik M; Jóźwiak S; Jurkiewicz E; Perek D; Kotulska K
Eur J Paediatr Neurol; 2012 Jan; 16(1):83-5. PubMed ID: 22000822
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
12. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
Jia J; Xiong L; Chen S
N Engl J Med; 2011 Feb; 364(6):577. PubMed ID: 21306252
[No Abstract] [Full Text] [Related]
13. Regression of a cardiac rhabdomyoma in a patient receiving everolimus.
Tiberio D; Franz DN; Phillips JR
Pediatrics; 2011 May; 127(5):e1335-7. PubMed ID: 21464184
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
Franz DN; Leonard J; Tudor C; Chuck G; Care M; Sethuraman G; Dinopoulos A; Thomas G; Crone KR
Ann Neurol; 2006 Mar; 59(3):490-8. PubMed ID: 16453317
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
16. Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.
Wiemer-Kruel A; Woerle H; Strobl K; Bast T
Neuropediatrics; 2014 Apr; 45(2):129-31. PubMed ID: 24293099
[TBL] [Abstract][Full Text] [Related]
17. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
Nawashiro H; Shinomiya N
N Engl J Med; 2011 Feb; 364(6):576-7; author reply 577. PubMed ID: 21306253
[No Abstract] [Full Text] [Related]
18. American Society of Clinical Oncology 2011 CNS tumors update.
Ahluwalia MS
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1495-7. PubMed ID: 21999122
[TBL] [Abstract][Full Text] [Related]
19. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
Jozwiak J; Jozwiak S; Oldak M
Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
[TBL] [Abstract][Full Text] [Related]
20. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.
Aguilera D; Flamini R; Mazewski C; Schniederjan M; Hayes L; Boydston W; Castellino RC; MacDonald TJ
J Pediatr Hematol Oncol; 2014 Oct; 36(7):e448-51. PubMed ID: 24276039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
